Ultragenyx Pharmaceutical Inc.
RARE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001515673
In the last 90 days, Ultragenyx Pharmaceutical Inc. insiders filed 0 open-market purchases and 5 sales; 311 institutions reported holding it in 13F filings for Q2 2026, worth $3.55B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Ultragenyx Pharmaceutical Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 3 insiders, $339.7K in total
- Insiders trading
- 3
- Net value
- −$339.7K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Ultragenyx Pharmaceutical Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Huizenga Theodore Alan | SVP, Chief Accounting Officer | 67,863 | Sep 15, 2026 | 5 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer | 92,562 | Aug 4, 2026 | 5 |
| Horn Howard | Chief Financial Officer | 96,295 | Aug 4, 2026 | 11 |
| Sanders Corazon (Corsee) D. | Director | 21,095 | Jun 15, 2026 | 2 |
| Welch Daniel G | Director | 40,441 | May 18, 2026 | 1 |
| Dunsire Deborah | Director | 38,566 | May 18, 2026 | 1 |
| Narachi Michael | Director | 40,441 | May 18, 2026 | 1 |
| Fust Matthew K | Director | 33,696 | May 18, 2026 | 1 |
| Suliman Shehnaaz | Director | 27,951 | May 18, 2026 | 1 |
| Ray Amrit | Director | 31,116 | May 18, 2026 | 1 |
| Crombez Eric | EVP and Chief Medical Officer | 111,189 | May 6, 2026 | 3 |
| Kakkis Emil D | President & CEO | 735,739 | Apr 20, 2026 | 2 |
| Huang Dennis Karl | See Remarks | 147,845 | Apr 20, 2026 | 2 |
| Pinion John Richard | See Remarks | 133,142 | Apr 20, 2026 | 2 |
| Harris Erik | EVP & Chief Commercial Officer | 118,410 | Apr 20, 2026 | 2 |
| Kassberg Thomas Richard | CBO & EVP | 264,730 | Mar 4, 2025 | 0 |
| Bedrosian Camille L | EVP and Chief Medical Officer | 46,720 | Mar 3, 2023 | 0 |
| Dier Mardi | CFO & Executive Vice President | 66,695 | Oct 17, 2022 | 0 |
| Ekman Lars | Director | 17,745 | Jun 28, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 8, 2021 (view filing) | Jul 6 | 2 days | Harris ErikEVP & Chief Commercial Officer | SSale | −375 | $91.53 | −$34.3K | −1.5%25.3K after | |
| Sep 2, 2021 (view filing) | Sep 1-2 | 1 day | Bedrosian Camille LEVP and Chief Medical Officer | SSale | −5.00K | $100.11 | −$500.5K | −11.4%38.8K after | 2 lots |
| Sep 9, 2021 (view filing) | Sep 8 | 1 day | Parschauer Karah HerdmanEVP and General Counsel | SSale | −7.34K | $100.65 | −$738.4K | −20.4%28.7K after | |
| Oct 14, 2021 (view filing) | Oct 12-14 | 2 days | Dier MardiCFO & Executive Vice President | SSale | −6.74K | $82.00 | −$552.5K | −14.8%38.8K after | 2 lots |
| Oct 18, 2021 (view filing) | Oct 14 | 4 days | Pinion John RichardSee Remarks | SSale | −358 | $81.14 | −$29.0K | −0.7%49.8K after | |
| Oct 18, 2021 (view filing) | Oct 14 | 4 days | Parschauer Karah HerdmanEVP and General Counsel | SSale | −310 | $81.14 | −$25.2K | −1.1%28.4K after | |
| Oct 18, 2021 (view filing) | Oct 14 | 4 days | Kassberg Thomas RichardCBO & EVP | SSale | −286 | $81.14 | −$23.2K | −0.1%216.3K after | |
| Oct 18, 2021 (view filing) | Oct 14 | 4 days | Huizenga Theodore AlanSVP, Chief Accounting Officer | SSale | −140 | $81.14 | −$11.4K | −1.0%14.1K after | |
| Oct 18, 2021 (view filing) | Oct 14 | 4 days | Huang Dennis KarlEVP & Chief Tech Ops Officer | SSale | −358 | $81.14 | −$29.0K | −0.9%40.1K after | |
| Oct 18, 2021 (view filing) | Oct 14 | 4 days | Harris ErikEVP & Chief Commercial Officer | SSale | −303 | $81.14 | −$24.6K | −1.2%25.0K after | |
| Oct 18, 2021 (view filing) | Oct 14 | 4 days | Bedrosian Camille LEVP and Chief Medical Officer | SSale | −359 | $81.14 | −$29.1K | −0.9%38.4K after | |
| Feb 1, 2022 (view filing) | Jan 30 | 2 days | Bedrosian Camille LEVP and Chief Medical Officer | SSale | −1.66K | $66.30 | −$109.9K | −4.3%36.8K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Bedrosian Camille LEVP and Chief Medical Officer | SSale | −2.82K | $66.62 | −$187.9K | −7.7%33.9K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Kassberg Thomas RichardCBO & EVP | SSale | −2.37K | $66.62 | −$158.2K | −1.1%213.8K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Parschauer Karah HerdmanEVP and Chief Legal Officer | SSale | −2.89K | $66.62 | −$192.3K | −10.2%25.5K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Huang Dennis KarlSee Remarks | SSale | −3.23K | $66.62 | −$215.4K | −8.1%36.9K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Huizenga Theodore AlanSVP, Chief Accounting Officer | SSale | −843 | $66.62 | −$56.2K | −6.0%13.2K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Pinion John RichardSee Remarks | SSale | −4.50K | $66.62 | −$299.7K | −9.0%45.3K after | |
| Mar 3, 2022 (view filing) | Mar 1 | 2 days | Harris ErikEVP & Chief Commercial Officer | SSale | −2.71K | $66.62 | −$180.7K | −10.8%22.3K after | |
| Mar 3, 2022 (view filing) | Mar 1-3 | 2 days | Dier MardiCFO & Executive Vice President | SSale | −954 | $65.71 | −$62.7K | −1.8%51.8K after | 2 lots |
| Mar 8, 2022 (view filing) | Mar 7 | 1 day | Parschauer Karah HerdmanEVP and Chief Legal Officer | SSale | −5.14K | $62.95 | −$323.6K | −13.0%34.4K after | |
| Mar 15, 2022 (view filing) | Mar 11 | 4 days | Kassberg Thomas RichardCBO & EVP | SSale | −10.3K | $67.01 | −$688.9K | −4.3%227.6K after | |
| Apr 19, 2022 (view filing) | Apr 16 | 3 days | Huizenga Theodore AlanSVP, Chief Accounting Officer | SSale | −132 | $84.55 | −$11.2K | −0.8%16.9K after | |
| Jun 22, 2022 (view filing) | Jun 19 | 3 days | Harris ErikEVP & Chief Commercial Officer | SSale | −295 | $54.78 | −$16.2K | −0.8%36.2K after | |
| Oct 14, 2022 (view filing) | Oct 12 | 2 days | Dier MardiCFO & Executive Vice President | SSale | −3.48K | $38.22 | −$133.2K | −4.9%68.3K after | |
| Oct 17, 2022 (view filing) | Oct 14 | 3 days | Dier MardiCFO & Executive Vice President | SSale | −1.63K | $40.16 | −$65.4K | −2.4%66.7K after | |
| Dec 22, 2022 (view filing) | Dec 21 | 1 day | Huizenga Theodore AlanSVP, Chief Accounting Officer | SSale | −2.03K | $43.96 | −$89.3K | −11.1%16.2K after | |
| Jan 3, 2023 (view filing) | Dec 30, 2022 | 4 days | Kakkis Emil DPresident & CEO | SSale | −19.6K | $45.57 | −$892.4K | −3.5%541.1K after | |
| Mar 2, 2023 (view filing) | Feb 28 | 2 days | Huizenga Theodore AlanSVP, Chief Accounting Officer | SSale | −639 | $43.40 | −$27.7K | −3.9%15.6K after | |
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Harris ErikEVP & Chief Commercial Officer | SSale | −3.66K | $45.25 | −$165.8K | −6.0%57.3K after | |
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Pinion John RichardSee Remarks | SSale | −3.75K | $45.26 | −$170.0K | −4.5%80.2K after | |
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Huang Dennis KarlSee Remarks | SSale | −389 | $45.65 | −$17.8K | −0.5%75.3K after | |
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Huizenga Theodore AlanSVP, Chief Accounting Officer | SSale | −100 | $45.65 | −$4.57K | −0.4%23.0K after | |
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Kassberg Thomas RichardCBO & EVP | SSale | −1.97K | $45.27 | −$89.1K | −0.8%250.3K after | |
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Parschauer Karah HerdmanEVP and Chief Legal Officer | SSale | −3.16K | $45.25 | −$143.0K | −5.3%56.1K after | |
| Mar 3, 2023 (view filing) | Mar 1 | 2 days | Bedrosian Camille LEVP and Chief Medical Officer | SSale | −3.88K | $45.25 | −$175.6K | −7.7%46.7K after | |
| May 5, 2023 (view filing) | May 4 | 1 day | Parschauer Karah HerdmanEVP and Chief Legal Officer | SSale | −4.38K | $45.00 | −$197.0K | −7.8%52.0K after | |
| May 19, 2023 (view filing) | May 18 | 1 day | Pinion John RichardSee Remarks | SSale | −2.01K | $50.00 | −$100.6K | −2.6%74.7K after | |
| Jun 9, 2023 (view filing) | Jun 8 | 1 day | Sanders Corazon (Corsee) D.Director | SSale | −1.49K | $51.65 | −$76.7K | −13.4%9.57K after | |
| Jun 21, 2023 (view filing) | Jun 19 | 2 days | Harris ErikEVP & Chief Commercial Officer | SSale | −305 | $48.20 | −$14.7K | −0.5%57.3K after | |
| Jun 30, 2023 (view filing) | Jun 30 | Same day | Sanders Corazon (Corsee) D.Director | SSale | −585 | $46.76 | −$27.4K | −6.1%8.98K after | |
| Sep 6, 2023 (view filing) | Sep 1 | 5 days | Huizenga Theodore AlanSVP, Chief Accounting Officer | SSale | −970 | $37.15 | −$36.0K | −3.9%23.8K after | 2 lots |
| Sep 6, 2023 (view filing) | Sep 5 | 1 day | Harris ErikEVP & Chief Commercial Officer | SSale | −6.00K | $37.96 | −$227.8K | −10.5%51.3K after | |
| Sep 11, 2023 (view filing) | Sep 7 | 4 days | Huizenga Theodore AlanSVP, Chief Accounting Officer | SSale | −2.16K | $40.80 | −$88.2K | −8.4%23.6K after | 2 lots |
| Oct 23, 2023 (view filing) | Oct 19 | 4 days | Kakkis Emil DPresident & CEO | SSale | −47.9K | $33.52 | −$1.60M | −7.4%599.7K after | |
| Oct 24, 2023 (view filing) | Oct 23 | 1 day | Kassberg Thomas RichardCBO & EVP | SSale | −39.9K | $32.78 | −$1.31M | −13.9%246.9K after | 10b5-1 |
| Jan 2, 2024 (view filing) | Dec 29, 2023 | 4 days | Kakkis Emil DPresident & CEO | SSale | −30.0K | $47.87 | −$1.44M | −5.0%569.8K after | |
| Feb 8, 2024 (view filing) | Feb 7 | 1 day | Kakkis Emil DPresident & CEO | SSale | −30.0K | $45.00 | −$1.35M | −5.3%539.8K after | |
| Mar 5, 2024 (view filing) | Mar 1 | 4 days | Harris ErikEVP & Chief Commercial Officer | SSale | −4.77K | $53.76 | −$256.3K | −6.6%67.2K after | |
| Mar 5, 2024 (view filing) | Mar 1 | 4 days | Crombez EricEVP and Chief Medical Officer | SSale | −1.24K | $53.76 | −$66.6K | −2.5%48.9K after |